Earnings Call/Transcript
Gaudium IVF Q1 FY27 Earnings Call
Gaudium IVF and Women Health Ltd: Earnings conference call to discuss unaudited standalone and consolidated results for quarter ended June 30, 2026, scheduled on 2026-08-14 at 02:00 PM IST.

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q4 FY26
Bearish
2
Neutral
4
Bullish
8
Bearish
20
Neutral
12
Bullish
14
Bearish
18
Neutral
8
Bullish
6
Bearish
2
Neutral
4
Bullish
8
Bearish
2
Neutral
4
Bullish
8
Bearish
18
Neutral
8
Bullish
6
Bearish
18
Neutral
8
Bullish
6
Bearish
18
Neutral
8
Bullish
6
Healthcare Services
Healthcare Service Provider
898 Cr
High Risk
36.7
66.1
1.2
5.9
163.70
69.50
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Gaudium IVF and Women Health Ltd (GAUDIUMIVF) is currently trading at 125.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gaudium IVF and Women Health Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Gaudium IVF and Women Health Ltd has traded between a low of ₹69.50 and a high of ₹163.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gaudium IVF and Women Health Ltd has a market capitalization of approximately 897.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gaudium IVF and Women Health Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 897.83 Cr, Gaudium IVF and Women Health Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gaudium IVF and Women Health Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gaudium IVF and Women Health Ltd is 36.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Earnings Call/Transcript
Gaudium IVF and Women Health Ltd: Earnings conference call to discuss unaudited standalone and consolidated results for quarter ended June 30, 2026, scheduled on 2026-08-14 at 02:00 PM IST.
Earnings Call/Transcript
Gaudium IVF and Women Health Ltd will hold an earnings conference call to discuss unaudited standalone and consolidated results for Q1 FY27 on 2026-08-14 at 02:00 PM IST.
Board Meeting
Gaudium IVF and Women Health Ltd: Board meeting on 2026-08-13 to consider and approve unaudited standalone and consolidated financial results for quarter ended June 30, 2026; trading window closed for designated persons.
Board Meeting
Gaudium IVF and Women Health Ltd: Board meeting scheduled on 2026-08-13 to consider and approve unaudited standalone and consolidated financial results for quarter ended 30-06-2026. Trading window closed from 2026-07-01 until 48 hours post-results.